Want to see FR:DIM full AI Analyst Report?
Top Page
Sartorius Stedim Biotech
(DIM)
Select Model
Select Model
Rating:53Neutral
Price Target:
€166.00
▼(-0.78% Downside)
Action:Reiterated
Date:07/24/26
The score is primarily supported by improving financial performance (strong TTM revenue rebound and better leverage), but is held back by still-recovering margins and weak free cash flow conversion. Technical indicators are bearish with the price below major moving averages and negative MACD. Valuation further constrains the score due to a high P/E and minimal dividend yield.
Positive Factors
Recurring consumables revenue
Sartorius Stedim’s business model includes high-frequency consumables (single-use assemblies, filtration consumables) that create durable, repeatable revenue and strong customer stickiness. Consumable pull-through from installed capital equipment supports predictable demand and long-term revenue visibility.
Negative Factors
Profitability below prior peaks
Margins remain materially below historical highs, suggesting persistent cost, mix, or pricing pressures. Sustained margin compression reduces return on invested capital, limits cash available for strategic initiatives, and means the company must rely on volume growth to restore profitability over several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables revenue
Sartorius Stedim’s business model includes high-frequency consumables (single-use assemblies, filtration consumables) that create durable, repeatable revenue and strong customer stickiness. Consumable pull-through from installed capital equipment supports predictable demand and long-term revenue visibility.
Read all positive factors
Sartorius Stedim Biotech (DIM) vs. iShares MSCI France ETF (EWQ)
Market Cap
€16.22B
Dividend Yield0.41%
Average Volume (3M)78.09K
Price to Earnings (P/E)55.2
Beta (1Y)1.43
Revenue Growth3.76%
EPS Growth29.94%
CountryFR
Employees10,265
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)3.02
Shares Outstanding97,330,410
10 Day Avg. Volume78,938
30 Day Avg. Volume78,094
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€230.00Price Target Upside37.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)5.01
Revenue Forecast (FY)€3.14B
Sartorius Stedim Biotech Business Overview & Revenue Model
Company Description
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental component...
How the Company Makes Money
Sartorius Stedim Biotech primarily generates revenue by selling bioprocessing products and related services to biopharmaceutical and biotechnology customers. A major component of its model is a recurring consumables stream: single-use assemblies (...
Sartorius Stedim Biotech Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
66
Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.01B | 2.97B | 2.78B | 2.78B | 3.49B | 2.89B |
| Gross Profit | 1.35B | 1.35B | 1.21B | 1.23B | 1.82B | 1.55B |
| EBITDA | 886.60M | 867.10M | 670.50M | 755.70M | 1.33B | 811.96M |
| Net Income | 292.60M | 265.60M | 175.10M | 309.70M | 876.10M | 414.40M |
Balance Sheet | ||||||
| Total Assets | 7.92B | 8.02B | 8.26B | 7.74B | 5.07B | 3.95B |
| Cash, Cash Equivalents and Short-Term Investments | 203.90M | 434.20M | 688.80M | 126.10M | 133.00M | 237.35M |
| Total Debt | 2.40B | 2.60B | 2.87B | 3.68B | 1.14B | 625.52M |
| Total Liabilities | 3.67B | 3.89B | 4.23B | 5.07B | 2.55B | 2.22B |
| Stockholders Equity | 4.24B | 4.09B | 3.99B | 2.64B | 2.45B | 1.66B |
Cash Flow | ||||||
| Free Cash Flow | 220.70M | 145.40M | 475.30M | 156.10M | 181.70M | 371.98M |
| Operating Cash Flow | 615.10M | 538.60M | 815.10M | 629.70M | 612.30M | 695.97M |
| Investing Cash Flow | -468.80M | -397.70M | -340.00M | -2.72B | -957.50M | -465.23M |
| Financing Cash Flow | -643.20M | -389.20M | 84.90M | 1.99B | 220.70M | -69.27M |
Sartorius Stedim Biotech Technical Analysis
Negative
167.30
Price Trends
175.67
Negative
171.41
Negative
183.79
Negative
Market Momentum
-2.45
Positive
43.25
Neutral
37.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:DIM, the sentiment is Negative. The current price of 167.3 is below the 20-day moving average (MA) of 176.45, below the 50-day MA of 175.67, and below the 200-day MA of 183.79, indicating a bearish trend. The MACD of -2.45 indicates Positive momentum. The RSI at 43.25 is Neutral, neither overbought nor oversold. The STOCH value of 37.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:DIM.
Sartorius Stedim Biotech Peers Comparison
UnderperformOutperform
Sector (55)
FR:DIM
Sartorius Stedim Biotech
171.90
2.59
1.53%
FR:BIM
bioMerieux
72.25
-51.55
-41.64%
FR:ERF
Eurofins Scientific
67.74
1.98
3.01%
Sartorius Stedim Biotech Corporate Events
Sartorius Stedim Biotech Delivers H1 Growth and Confirms 2026 Outlook
Jul 23, 2026
Sartorius Stedim Biotech reported first-half 2026 sales of €1.53 billion, with operating sales up 8% at constant exchange rates, driven mainly by recurring consumables and a return to slight growth in bioprocess equipment. Underlying EBITDA ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.